A 12-hour rapid titration method for cancer pain: a randomized, controlled, open-label study

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Opioid titration is crucial for balancing pain relief and side effects in moderate-to-severe cancer pain.
• Rapid dose titration aims for early analgesia.
• This study investigated a 12-hour rapid dose titration for cancer pain efficacy and safety.

Purpose of the Study:

• To evaluate the efficacy and safety of a 12-hour rapid dose titration regimen for moderate-to-severe cancer pain.
• To compare oxycodone and morphine in a rapid titration protocol.
• To assess pain control, breakthrough pain, and quality of life.

Main Methods:

• 106 opioid-naïve patients with moderate-to-severe cancer pain were randomized into oxycodone and morphine groups.
• Medications were adjusted to oxycodone sustained-release tablets after 12 hours, with subsequent 12-hour adjustments.
• Analgesic efficacy and adverse reactions were monitored up to 72 hours.

Main Results:

• Overall pain control reached 96.2% at 24 hours, with no significant group difference.
• Oxycodone group showed a significantly higher proportion of patients with ≥50% Numeric Rating Scale (NRS) score decrease (P=0.013).
• Oxycodone group experienced fewer breakthrough pain episodes and reported significantly improved quality of life at 24 hours (P=0.047).
• Only mild (grade 1 or 2) adverse reactions were observed, with no significant intergroup differences.

Conclusions:

• The 12-hour rapid dose titration method achieves early analgesia with mild adverse reactions.
• Rapid titration using background sustained-release oxycodone effectively reduces breakthrough pain episodes.
• This approach provides significant early pain relief and enhances patient quality of life.